checkAd

    PureTech Health  109  0 Kommentare Results of Annual General Meeting

    The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Thursday, June 13, 2024.

    All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.

    Resolutions

    For

    %

    Against

    %

    Withheld

    Total votes cast

    001. To approve the Company’s Annual Report and Accounts for year ended 31 December 2023

    180,831,234

    100.00%

    3,581

    0.00%

    90,476

    180,834,815

    002. To approve the Directors’ Remuneration Report

    72,296,583

    55.95%

    56,922,574

    44.05%

    51,706,134

    129,219,157

    003. To approve the Directors’ Remuneration Policy

    83,722,702

    64.46%

    46,157,643

    35.54%

    51,044,946

    129,880,345

    004. To approve amendments to the rules of the PureTech Health plc Performance Share Plan 2023

    91,600,947

    70.74%

    37,887,028

    29.26%

    51,437,316

    129,487,975

    005. To elect Ms. Sharon Barber-Lui as a director

    180,223,191

    99.99%

    13,818

    0.01%

    688,282

    180,237,009

    006. To elect Dr. Bharatt Chowrira as a director

    180,903,972

    99.99%

    14,250

    0.01%

    7,069

    180,918,222

    007. To elect Dr. Raju Kucherlapati as a director

    168,304,704

    93.03%

    12,613,517

    6.97%

    7,070

    180,918,221

    008. To elect Dr. John LaMattina as a director

    97,660,582

    74.71%

    33,063,035

    25.29%

    50,201,674

    130,723,617

    009. To elect Dr. Robert Langer as a director

    178,992,250

    98.94%

    1,925,771

    1.06%

    7,270

    180,918,021

    010. To elect Ms. Kiran Mazumdar-Shaw as a director

    171,626,767

    94.91%

    9,206,455

    5.09%

    92,069

    180,833,222

    011. To reappoint PricewaterhouseCoopers LLP as Auditors of the Company

    180,817,973

    99.95%

    95,238

    0.05%

    12,080

    180,913,211

    012. To authorize the Audit Committee to determine the Auditors' remuneration

    180,898,936

    99.99%

    20,477

    0.01%

    5,878

    180,919,413

    013. To authorize the allotment of shares

    168,771,484

    97.85%

    3,707,621

    2.15%

    8,446,186

    172,479,105

    014. To disapply pre-emption rights

    167,217,234

    96.95%

    5,261,591

    3.05%

    8,446,466

    172,478,825

    015. To further disapply pre-emption rights for acquisitions and specified capital investments.

    165,299,824

    95.84%

    7,179,001

    4.16%

    8,446,466

    172,478,825

    016. To authorize market purchase of own shares

    180,789,891

    99.93%

    129,498

    0.07%

    5,902

    180,919,389

    017. To authorize general meetings to be called on not less than 14 clear days’ notice

    180,302,971

    99.77%

    422,112

    0.23%

    200,208

    180,725,083

    While the Board is pleased that all resolutions were supported by the required majorities, we note that more than 20% of votes were cast against Resolutions 2, 3, 4 and 8. Over the past year, the Board has actively engaged with shareholders regarding its approach to director remuneration, resulting in adjustments to the proposed Remuneration Policy. Looking ahead, the Board will continue to engage with shareholders to further understand their perspectives and the reasons behind their opposition to certain proposals. In accordance with the UK Corporate Governance Code, we will provide an update on our engagement efforts within the next six months.

    Notes:

    (1)

    A vote “Withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.

     

    (2)

    As at June 13, 2024 the number of issued shares in the Company was 270,859,250 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

     

    (3)

    The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company’s website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.

    About PureTech Health

    PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech’s R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

    For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains statement that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our future prospects, developments, and strategies, and statements regarding the intent, belief or current expectations regarding the Tender Offer. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.


    The PureTech Health Stock at the time of publication of the news with a raise of +0,78 % to 25,80USD on Frankfurt stock exchange (13. Juni 2024, 08:07 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    PureTech Health Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Thursday, June 13, 2024. All of the resolutions proposed at the Annual General Meeting were duly …